Complications of cosmetic iris implants: French series of 87 eyes.


Journal

Journal of cataract and refractive surgery
ISSN: 1873-4502
Titre abrégé: J Cataract Refract Surg
Pays: United States
ID NLM: 8604171

Informations de publication

Date de publication:
01 2020
Historique:
entrez: 13 2 2020
pubmed: 13 2 2020
medline: 7 2 2021
Statut: ppublish

Résumé

Iris intraocular implants were developed to manage congenital or traumatic iris defects. However, they are also used to change the color of patient eyes. The aim of this retrospective series was to report complications in patients managed in France after cosmetic implantation. Ophthalmological institutions and private ophthalmologists in France. Multicenter retrospective observational study. Questionnaires were sent to all ophthalmology departments in university hospitals and to private ophthalmologists. This questionnaire listed demographic and clinical data for each implanted eye with a focus on safety, the description of ocular complications (corneal edema, endothelial cell loss, increased intraocular pressure, and intraocular inflammation), and the therapeutic management implemented. Forty-four questionnaires (87 eyes) were collected, and ultimately, 33 questionnaires (65 eyes) were considered complete and analyzed. Two types of implants were identified. Of the 65 eyes analyzed, only 5 eyes (7.7%) did not experience any complication and 60 eyes (92.3%) had at least 1 complication. The most commonly reported complication was corneal decompensation (78.5%). The diagnosis of glaucoma was made in over half (52.3%) of the cases. Explantation was needed in 81.5% of cases. The mean final visual acuity was 0.45 ± 0.08 logarithm of the minimum angle of resolution (logMAR) (0 to 2 logMAR). Several ocular complications with a decreased mean visual acuity were described in a young healthy population. In addition, patient information on the safety of this procedure appeared insufficient.

Identifiants

pubmed: 32050230
doi: 10.1097/j.jcrs.0000000000000032
pii: 02158034-202001000-00007
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-39

Commentaires et corrections

Type : CommentIn

Auteurs

Hussam El Chehab (H)

Military Hospital of Desgenettes, Lyon, France (El Chehab and Dot); Rothschild Foundation, Paris, France (Gatinel); Quinze-Vingts National Ophthalmology Hospital, Paris, France (Baudouin); Charles-Nicolle Hospital, CHU de Rouen, Rouen, France (Muraine); Clinique Monticelli-Vélodrome, Marseille, France (Hoffart); Clinique Juge, Marseille, France (Rozot and Baïkoff); Hôtel-Dieu-Cochin Hospital, Paris, France (Mehanna and Bonnet); Clinique Sourdille, Nantes, France (Santiago); Édouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France (Burillon); Pasteur Hospital, Nice, France (Baillif); Bretonneau Hospital, Tours, France (Pisella); Nantes University Hospital, Nantes, France (Weber); Pellegrin Hospital, Bordeaux France (Robinet-Perrin); Private center, Toulon, France (Deidier); Private center, Nancy, France (Hay); Gui de Chauliac Hospital, Montpellier, France (Villain); Besancon University Hospital, Besancon, France (Gauthier); Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France (Mathis); and French Military Health Service Academy of Val de Grâce, Paris, France (Dot).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH